Clinical trials
Neovascular Age-related Macular Degeneration clinical trials
Below are recruiting neovascular age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07215234RecruitingPhase 1/Phase 2
Study of an injection for geographic atrophy in AMD
This study tests a single injection of an experimental drug (SAR446597) into the eye for people with geographic atrophy, a late-stage form of dry age-related macular degeneration. The goal is to see if it can safely slow vision loss.
Peoria, ArizonaAges 60 years+ - NCT02253030Recruiting
Eye scan study for newly diagnosed wet AMD
This study uses a special eye scan (OCT angiography) to look at new, abnormal blood vessel growth in people with wet age-related macular degeneration (wet AMD) who have not been treated yet. It may help researchers better understand the disease and how it changes over time.
Portland, OregonAges 50–100 - NCT07427160Recruiting
Study on best treatment for bleeding under the retina
This trial looks at whether the type of abnormal blood vessels under the retina affects how well a procedure (pneumatic displacement) works to move a macular hemorrhage (bleeding) out of the central vision area. It may help doctors choose the best approach for patients.
Trento, TrentoAges 50 years+ - NCT07434713Recruiting
Testing early response to Eylea 8mg for wet AMD
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
BernAges 50 years+ - NCT07500324Recruiting
Searching for new markers in age-related eye diseases
This study looks for proteins in the blood and eye fluids that may help doctors better understand and monitor three common eye conditions: age-related macular degeneration, diabetic retinopathy, and retinal detachment. If you have one of these conditions, or if you are a healthy control with no retinal disease, you may be able to help by giving a small sample of blood or fluid from your eye during a routine procedure.
Roma, ItalyAges 18 years+ - NCT07556406Recruiting
Eye imaging study for age-related macular degeneration
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
San Francisco, CaliforniaAges 55 years+ - NCT07660640Enrolling by invitation
Long-term follow-up for VOY-101 eye injection study
This study follows up with people who already received the VOY-101 injection for a type of age-related vision loss (non-neovascular age-related macular degeneration) in an earlier study. It checks how they are doing over a longer period of time.
Boston, MassachusettsAges 50 years+ - NCT07456826Enrolling by invitationPhase 4
Comparing two eye numbing gels for shots
This trial tests a new eye-numbing gel against the standard numbing method to see which works better for patients getting regular anti-VEGF injections in the eye.
Tyler, TexasAges 18 years+ - NCT03999801Enrolling by invitationPhase 2
Long-term follow-up for a subretinal eye treatment
This study checks how well a previous eye treatment (RGX-314) lasts over time. There is also an extra “other eye” study for people with age-related macular degeneration affecting both eyes.
Phoenix, ArizonaAges 50 years+ - NCT06595355RecruitingPhase 2/Phase 3
Study of eye injections with or without curcumin for diabetic eye swelling
This trial tests whether adding oral curcumin (a natural supplement) to standard eye injections (bevacizumab) improves treatment for diabetic macular edema, a swelling in the back of the eye that can affect vision.
Isfahan, Isfahan University of Medical SciencesAges 40 years+
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neovascular age-related macular degeneration?
- Yes. Clin2 currently lists 82 recruiting neovascular age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neovascular age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neovascular age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-Related Macular Degeneration
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.